Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers
Status:
Completed
Trial end date:
2020-12-28
Target enrollment:
Participant gender:
Summary
About 18 patients will take part in the phase 1 portion of the trial. In the beginning of the
study, 3 patients will be treated with a low dose of ganetespib (STA-9090) and the standard
dose of crizotinib. If this dose does not cause significant side effects, it will be
increased as new patients take part in the study. The study will only be open at Memorial
Sloan Kettering Cancer Center.